UCSF Helen Diller Comprehensive Cancer Center

University of California San Francisco

San Francisco, CA

Website

(888) 828-2206 Refer Patient

Filters

Help Me Find Trials

Sort by

Accepting patients

QUINTESSENTIAL

Phase 2 Study of BMS-986393, a GPRC5D-directed CART-Cell Therapy, in Participants with Relapsed or Refractory Multiple Myeloma

Learn more

CAR T Cell
GPRC5D
Phase 2

Not yet accepting

MonumenTAL-8

A Phase 2, Open-Label, Multicenter Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma

Learn more

Bispecific Antibody
CAR T Cell
BCMA
GPRC5D
Phase 2

Get personalized results in 60 seconds

All clinical trials have eligibility criteria - or a list of reasons why you may be able or unable to participate in a trial. Answer a few questions to view your personalized results - all in under 60 seconds.

Help me find trials

Accepting patients

BMS-986453

A Phase 1, Open-Label, Dose-Finding Study of BMS-986453, Dual Targeting BCMAxGPRC5D Chimeric Antigen Receptor T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma

Learn more

CAR T Cell
BCMA
GPRC5D
Phase 1

Not yet accepting

Talquetamab with Iberdomide

A Phase Ib, Multi-center, Study of Talquetamab in Combination With Iberdomide and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma

Learn more

Bispecific Antibody
CD3
GPRC5D
Phase 1

Accepting patients

PET Imaging

Pilot PET Imaging Study of [89Zr]DFO-YS5 for Detecting CD46 Positive Malignancy in Multiple Myeloma

Learn more

CD46
Phase 1

Accepting patients

IONA-MM

A Prospective, Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM)

Learn more

Patient Registry
Observational Trial

Accepting patients

JNJ-79635322

Phase 1, First-in-Human, Dose Escalation Study of JNJ-79635322, a Trispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated AL Amyloidosis

Learn more

BCMA
GPRC5D
Tri-specific Antibody
Phase 1

Not yet accepting

CARTITUDE-6

A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma (CARTITUDE-6)

Learn more